Uses
Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.
Source: US FDA prescribing information
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Carbachol is a cholinergic receptor agonist. It is available as ophthalmic solution. MedsAcross supplies Carbachol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Cholinergic Receptor Agonist, Cholinergic Agonists
- ATC classification
- B05XA04 Carbachol · Blood substitutes and infusion solutions, subgroup B05X, subgroup B05XAN07AB01 Carbachol · Choline esterS01EB02 Carbachol · Eye medicines, subgroup S01E, subgroup S01EB
- US FDA first approval
- 28 September 1972
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Ophthalmic
- Dosage forms
- Ophthalmic solution
- Identifiers
- UNII 8Y164V895YRxCUI 1999CAS 51-83-2DrugBank DB00411Q419401
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Source: US FDA prescribing information
Contraindications
Should not be used in those persons showing hypersensitivity to any of the components of this preparation.
Source: US FDA prescribing information
Warnings and precautions
For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease. The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.
Source: US FDA prescribing information
Side effects
Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported. Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol. The following additional reactions have been identified during post-approval use of MIOSTAT (carbachol intraocular solution, USP) 0.01% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.
Source: US FDA prescribing information
Storage
Store at 15° - 30°C (59° - 86°F). © 2021 Alcon Inc.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Carbachol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Miostat 0.1 mg/mL ophthalmic solutionOphthalmic | Alcon Laboratories | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 28 September 1972 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Carbachol in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Carbachol available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Carbachol and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Carbachol have?
The catalogue lists 1 brand names for Carbachol, including Miostat.
Is Carbachol approved by the US FDA?
Yes. The US FDA first approved Carbachol on 28 September 1972, according to Drugs@FDA.
Does Carbachol need cold chain shipping?
No listed presentation of Carbachol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Carbachol in?
Carbachol is classified under ATC code B05XA04 (Carbachol).
References
- MIOSTAT prescribing information (Alcon Laboratories). U.S. National Library of Medicine, DailyMed. Retrieved 10 February 2023
Request Carbachol for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.